M
Metavention
Medical devices to help with interventional therapies for type 2 diabetes
About Metavention
Metavention is a medical technology startup that operates in the healthcare sector, specifically focusing on the treatment of high blood pressure and other metabolic diseases. The company's primary offering is a unique treatment that disrupts overactive nerves contributing to high blood pressure, using a method known as Renal Denervation (RDN). RDN is a one-time, minimally invasive procedure that uses Metavention's proprietary iRF Denervation System to deliver radio frequency energy to targeted nerves. This energy generates heat that permanently disrupts the overactive nerves associated with the kidneys, potentially resulting in reduced blood pressure and improvement in other metabolic diseases.
Metavention's business model revolves around the development, testing, and commercialization of its iRF Denervation System. The company is currently conducting clinical studies to evaluate the safety and benefits of its treatment. Its primary clients are patients with high blood pressure and healthcare providers seeking innovative treatments for metabolic diseases.
The company generates revenue by selling its iRF Denervation System to healthcare providers and hospitals. It also stands to benefit from potential partnerships with larger pharmaceutical or medical device companies interested in its technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Maple Grove, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 56.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2018 | $65M | $260M | Sanderling Ventures · Versant Ventures · NEA | — |
Growth signals
Latest recorded traffic for Metavention is 10 monthly website visits, down 93.8% over the last three months. Metavention's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
NEA
Sanderling Ventures
Versant Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Metavention on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Metavention’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.